Abstract: Described are methods of treating cardiovascular diseases in smokers and/or subjects ingesting or consuming nicotine from other sources (e-cigarettes/vaping, smokeless tobacco, NRT, etc.

Abstract: Methods for detecting enhanced risk of opioid-induced respiratory dysfunction in patients with normal levels of oxygen saturation. The method may comprise: (1) assaying blood of the patient for a normal level of oxygen saturation; (2) measuring the patient's respiration rate at rest for a normal rate; and (3) correlating the normal level of oxygen saturation and the normal rate of respiration with enhanced risk of opioid-induced respiratory dysfunction if: (a) the patient is at an altitude of about 1000 feet above sea level or greater; or (b) the patient's oxygen saturation level is normal but no greater than about 95%; or (c) the patient received prior dosing with intravenous opioid and is converted to dosing with an oral opioid. The method may further comprise administering opioids to a patient after detecting whether there is an enhanced risk of opioid-induced respiratory dysfunction.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a one-hour average oral morphine equivalents, or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a one-hour average oral morphine equivalents, or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.

Abstract: The invention provides a method for relieving anxiety in a mammal using a compound of the formula ##STR1## wherein R is Benzyl or cyclohexyl, or a non-toxic pharmaceutically acceptable salt thereof. A preferred compound for use in the subject method is 1-methyl-3-{N-[(3'-benzyloxycarbonyl)propyl]}carbamoyl-1,4-dihydropyridine .

Abstract: A method of treatment of pychosexual dysfunction in male and female human beings by the administration of the compound of the formula (I) ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human being in need thereof.

Abstract: A method of treatment for reducing cholesterol in humans by the administration of the compound of the formula I ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human in need thereof.

Abstract: A method of Treatment of Minimal Brain Dysfunction (MBD) also known as ATTENTION DEFICIT DISORDER in humans by the administration of the compound of the formula I ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human in need thereof.

Abstract: A method of Treatment of Tardive Dyskinesia (TD) in humans by the administration of the compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human in need thereof.

Abstract: A method of suppressing prolactin secretion in humans by the administration of the compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof in a non-toxic, effective prolactin suppression amount (calculated as base) to a human in need thereof.